Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
https://www.zacks.com/stock/news/2248594/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2248594
Apr 01, 2024 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Wall Street Awaits Consumer Confidence Data
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
0
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
https://www.zacks.com/stock/news/2244204/acelyrin-slrn-up-on-data-from-thyroid-eye-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244204
Mar 21, 2024 - ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
0
The AI Race Gets Litigious
https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001
Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
0
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077
Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
0
Top Research Reports for NVIDIA, Visa & Amgen
https://www.zacks.com/commentary/2232860/top-research-reports-for-nvidia-visa-amgen?cid=CS-ZC-FT-research_daily-2232860
Feb 28, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V) and Amgen Inc. (AMGN).
0
Where Are Biotech ETFs Headed After Q4 Earnings?
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
0
PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2224255
Feb 09, 2024 - PBYI vs. AMGN: Which Stock Is the Better Value Option?
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4668054-amgen-inc-amgn-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 06, 2024 - Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q4 2023 Earnings Conference Call February 6, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway -...
0
Page 1>